The biotech patent landscape divides into platform IP (mRNA delivery, viral vectors, CRISPR systems — held by Moderna, BioNTech, Editas, Intellia) and asset IP (specific drugs and indications — held by every pharma company). Platform patents are the most strategically valuable because they enable entire pipelines.
The post-pandemic shift: mRNA platform patents, previously academic curiosities, generated over $100 billion in revenue from 2021-2023 alone — making them the highest-revenue patents in the history of the pharmaceutical industry.
Key Patents
Key Players
Moderna
mRNA platform leader, holding the foundational LNP and modified-nucleoside patents that enabled the first commercial mRNA vaccines. Pandemic revenue exceeded $100B, and the patent portfolio now anchors an entire pipeline of mRNA oncology, rare disease, and infectious disease programs — making Moderna's IP among the most commercially productive in pharmaceutical history.
BioNTech
Co-inventor of the modern mRNA vaccine in partnership with Pfizer, with the Karikó-Weissman modified nucleoside IP at the core. BioNTech's patent strategy extends beyond infectious disease into individualized cancer vaccines and CAR-T — leveraging its mRNA platform IP across the broadest therapeutic pipeline of any mRNA company.
Broad Institute
Holds the CRISPR eukaryotic application patents that govern almost every commercial therapeutic CRISPR program. The Broad has licensed its IP to Editas, Vertex, and most of the therapeutic CRISPR ecosystem — a non-profit institution wielding one of biotech's most commercially significant patent estates.
Regeneron
Built a $100B+ market cap on antibody platform IP — the VelocImmune humanized mouse system enables Regeneron and its licensees to discover fully human antibodies faster than any competing approach. The most prolific antibody drug developer of the modern era, with platform patents that underpin many bestselling biologics in oncology and immunology.
What to Watch
Generative Protein Design Patents
AlphaFold-derived methods, RFdiffusion, and de novo protein engineering filings are emerging from DeepMind, Generate Biomedicines, and Isomorphic Labs. The patents being filed now will define which companies can commercialize the next generation of computationally designed therapeutics — a category that did not exist five years ago.
Base & Prime Editing
Second-generation CRISPR methods from Beam Therapeutics, Verve, and Prime Medicine may displace traditional Cas9 by enabling precise single-letter edits without double-strand breaks. The patent estates being assembled around these techniques will determine whether the next wave of gene-editing therapies is dominated by Cas9 incumbents or by a new generation of platform companies.
Cell Therapy Manufacturing
The next decade of patent activity in cell therapy will center on in-vivo CAR-T (eliminating the need for ex-vivo manufacturing), allogeneic off-the-shelf cell products, and manufacturing methods that lower the per-patient cost from hundreds of thousands of dollars to a price that can scale beyond rare hematologic cancers.
From PatentBrief
Explore biotech patents on PatentBrief →
Search mRNA, CRISPR, antibody, and cell therapy patents. Read any patent in plain English and understand the claims that define the next generation of medicine.